Claritev Corporation (CTEV) AI Stock Analysis

Claritev Corporation provides data analytics and technology-enabled end-to-end cost management, payment, and revenue integrity solutions to the healthcare industry in the United States. Its offerings include claims intelligence solutions like reference-based pricing and surprise bill services, network solutions including primary and complementary networks, and payment and revenue integrity solutions such as clinical negotiation. The company also supplies data and analytics platforms like PlanOptix, CompleteVue, and BenInsights to commercial healthcare payers, third-party administrators, employers, and government healthcare payers. Formerly known as MultiPlan Corporation, the company rebranded to Claritev Corporation in February 2025.

Claritev Corporation posted revenue of $1.12B in FY2021 with gross margin of 84.3% and net income of $102.1M. Revenue subsequently contracted by 3.4% in FY2022 to $1.08B and by 10.9% in FY2023 to $961.5M. In FY2024, revenue dropped 3.2% to $930.6M alongside an operating margin of -149.4% and net income of -$1.65B. Performance improved in FY2025 as revenue rose 3.7% to $965.4M, though gross margin contracted to 27.6% and net income remained negative at -$284.3M. For the latest quarter ended June 30, 2026, quarterly revenue grew 6.6% year-over-year, contributing to trailing twelve-month revenue of $994.7M and an operating margin of 12.8%.

As of June 30, 2026, Claritev held $14.4M in cash and short-term investments compared to total debt of $4.62B, resulting in net debt of $4.61B. Total assets stood at $4.76B, and shareholders' equity was -$294.6M. The company reported a current ratio of 1.00. For FY2025, operating cash flow was $117.3M, capital expenditures were $129.6M, and free cash flow was -$12.3M. Its share count expanded by 4.2% over 5 years.

Claritev carries a market capitalization of $374.9M and an enterprise value of $5.10B. The stock trades at a forward P/E of 3.4x, below the 17.3x median of its US-listed Healthcare peers. Its price-to-sales multiple is 0.4x versus the peer median of 4.1x, and its EV/EBITDA is 10.7x compared to the peer median of 12.0x. Over the past year, CTEV fell 60.9% while the S&P 500 (SPY) gained 16.8%. Over five years, the stock dropped 88.1% compared to an 83.0% gain for SPY.

Wall Street analysts track CTEV with 2 Strong Buy, 2 Buy, and 1 Hold ratings, with 0 Sell or Strong Sell ratings. The mean price target is $46.00, representing an upside of 108.0% from the last close of $22.12 on October 16, 2026. For the fiscal year ending December 31, 2026, consensus estimates project revenue of $1.01B and EPS of $5.81, an increase of 146.2%. The company has beaten EPS estimates in 1 of the last 4 quarters, and its next earnings date is November 9, 2026.

This page is an AI-written research summary of Claritev Corporation (CTEV). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: CTEV income statement, CTEV balance sheet, CTEV key metrics, CTEV analyst forecast, CTEV chart. See the CTEV stock overview for the latest quote and news.